Pipeline
New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression
Unveiled at ARVO 2026, DOT lenses saved more than 1 D of myopic progression on average after 2 years among 6-to-10-year-old wearers.
Research
Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression
Latest 12-month data details highest myopia-control efficacy results reported to date in myopes as young as age 4 wearing HOYA’s D.I.M.S. technology.
Research
Study links poor diet with increased pediatric myopia
Cross-sectional study finds diets heavy in processed and sugar foods increase risk, while those rich in nuts, legumes, and whole grains appear protective.
Pipeline
Sydnexis's low-dose atropine shows strong phase 3 efficacy for pediatric myopia
Recent 3-year data from the STAR trial meets primary and secondary endpoints for SYD-101, including the greatest treatment benefits among younger myopes.
Events
Registration opens for Eyes On Myopia 2026
Virtual event kicks off May 9 in partnership with Woo University, offering up to 5 hours of COPE-accredited CE credits.
Research
Lutein shows potential as myopia management supplement
Preliminary RCT data highlights preservation of choroidal thickness in children taking lutein supplements.
Research
HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia
Interim results find advanced lens and D.I.M.S. triple enhanced design tech to be twice as effective in controlling axial elongation and disease progression.
Research
Conflicting evidence surrounds astigmatism's role in myopia
Study highlights need for further investigation into the impact of astigmatism on myopia onset and progression.
Products
Euclid Vision launches new SiHy daily disposable lens for myopia
The Be Free Day soft lens for pediatric myopes features BHVI's proprietary dual action, multistep optical design technology.
Research
Essilor Stellest 2.0 lenses demonstrate superior efficacy in slowing myopia progression
Upgraded FDA-authorized spectacle lenses for pediatric myopia control found to slow axial elongation more effectively after 1 year with advanced technology.
Pipeline
Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia
The STAR study met both primary and secondary endpoints for low-dose atropine formulation—just days after the FDA’s NDA rejection.
Research
Myopia may delay DR development and progression
Study used Mendelian randomization to identify a causal relationship between myopia and diabetic retinopathy.
Products
Myopia Profile debuts AI virtual assistant for disease management
Ask Kate is trained to deliver real-time, evidence-based responses to help ECPs stay updated on the latest clinical and scientific research.
Events
GMAC launches free myopia awareness toolkit for ECPs
Downloadable resources include take-home brochures, social media graphics, and more to raise awareness and education of pediatric disease progression.
Research
National trial to test preventative atropine drops for pediatric myopia
The University of Houston and The Ohio State University researchers partner on NEI-funded study to test if low-concentrated drops delay onset of myopia.
Research
Do seasonal variations impact myopia treatment efficacy?
Researchers investigate whether the effect of orthokeratology varies base don the season.
Pipeline
iVeena submits IND to FDA for pediatric myopia clinical trial
Company plans to initiate a multinational phase 2 study on IVMED-85, a PF and non-atropine daily eye drop intended to improve refraction and decrease AE rates.Pipeline
New DOT lens data finds 75% pediatric myopia management efficacy after 12 months
Latest clinical results support safety and effectiveness of SightGlass Vision’s Diffusion Optics Technology spectacle lenses—including 1-year following discontinued wear.
Research
MiSight 1 day lens 7-year data supports long-term myopia control
Clinical study on dual-focus contact lens notes retained treatment gains among myopic eyes even after discontinued wear.
Research